420 with CNW – Former NHL Players to Participate in Post-Concussion Cannabis Treatment Trial

March 25, 2019 04:20:11

Dozens of former National Hockey League (NHL) players will receive cannabis as part of a study to investigate the effects of CBD on brain injuries.

Dr. Charles Tator, a neurosurgeon and concussion expert, says that his team hopes that CBD will exhibit a therapeutic effect on the former players who suffer from chronic pain and other symptoms of repetitive brain injury.

For this study, the researchers recruited about 100 former NHL players to participate as research subjects.

Half of those people will receive a placebo while the rest will be given CBD. All the study subjects will continue taking any other medication that they were taking for their symptoms.

The researchers will observe these individuals for 12 months and assess whether CBD had any impact on their illnesses. The research is slated to begin this summer.

This research is being conducted in order to find an alternative to the addictive and harmful opioids that athletes take for chronic pain and the other symptoms resulting from the head injuries that they sustain during their playing days.

It is estimated that nearly two out of ten people who sustain sports-related concussion end up with chronic symptoms after the concussion. These symptoms include chronic headaches.

The players also develop emotional problems, such as depression and anxiety. Many of these former players live a miserable life once they are out of the limelight because little attention is directed to them if they aren’t actively playing.

It is such realities that have prompted the NHL Alumni, the Canadian marijuana company Canopy Growth and Neeka Health to team up and conduct this research.

The researchers hope that the complex and multidimensional study that they have taken on will provide valuable insights into how CBD interacts with the behaviors and brains of former NHL players struggling with the symptoms linked to the aftermath of suffering concussions.

This particular study isn’t the first in this area. For example, an earlier study conducted by a team of researchers from Miami University found that a combination of CBD and an anesthetic (NDMA) was effective in improving the condition of test animals that had brain injuries. This team of researchers is now conducting a human study to see what parallels emerge between their animal study and the human one.

The entire cannabis industry, especially FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) and Generation Alpha, Inc. (OTCQB: GNAL), hopes that the studies confirm that cannabis is not only viable but also better at treating the post-concussion symptoms.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office